Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H43N7O7 |
| Molecular Weight | 589.6837 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCC\C=C\C=C\C(=O)NCC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](NC2=C3N=CNC3=NC=N2)O[C@H]1[C@@H](O)CO
InChI
InChIKey=LQIPDFIUPOYMPR-BKYURJJWSA-N
InChI=1S/C28H43N7O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-19(38)29-14-20(39)34-21-23(40)24(41)28(42-25(21)18(37)15-36)35-27-22-26(31-16-30-22)32-17-33-27/h10-13,16-18,21,23-25,28,36-37,40-41H,2-9,14-15H2,1H3,(H,29,38)(H,34,39)(H2,30,31,32,33,35)/b11-10+,13-12+/t18-,21+,23+,24+,25-,28-/m0/s1
| Molecular Formula | C28H43N7O7 |
| Molecular Weight | 589.6837 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial. | 2012-04 |
|
| Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. | 2000-06 |
|
| Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. | 1994 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:12:49 GMT 2025
by
admin
on
Mon Mar 31 18:12:49 GMT 2025
|
| Record UNII |
8VH13L5K20
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
434414
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
||
|
FDA ORPHAN DRUG |
385312
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
||
|
NCI_THESAURUS |
C1594
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8VH13L5K20
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY | |||
|
650426
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY | |||
|
DTXSID60873333
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY | |||
|
151276-95-8
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY | |||
|
DB15215
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY | |||
|
C1614
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY | NCIT | ||
|
6440176
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY | |||
|
KRN-5500
Created by
admin on Mon Mar 31 18:12:49 GMT 2025 , Edited by admin on Mon Mar 31 18:12:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |